Stomach Cancer Treatment Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 6.08 Bn

Forecast Year, 2035

USD 19.42 Bn

CAGR, 2026 - 2035

12.31%

Report Coverage

Global

What is the Stomach Cancer Treatment Market Size?

The global stomach cancer treatment market size was evaluated at USD 6.08 billion in 2025 and is predicted to reach around USD 19.42billion by 2035, expanding at a CAGR of 12.31% from 2026 to 2035. The demand for the stomach cancer treatment market is increasing due to the rise in global cancer incidences. This promotes the adoption of technologies that can help in providing therapies to patients.

Stomach Cancer Treatment Market Key Takeaways

• Asia Pacific dominated the global market with the largest market share of 56% in 2025.
• Middle East and Africa are anticipated to grow at the highest CAGR during the forecast period.
• By treatment type, the targeted therapy segment contributed the highest market share of 40% in 2025.
• By treatment type, the immunotherapy segment is projected to grow at the fastest CAGR of 17.03% in the future years.
• By disease indication, the gastric cancer/gastroesophageal junction cancer segment captured the biggest market share of 85% in 2025.
• By disease indication, the gastrointestinal stromal tumors segment is expected to grow significantly during the forecast period.
• By drug class, the PD-1/PD-L1 inhibitors segment is expected to grow at the highest CAGR during the forecast period.
• By route of administration, the injectable treatment segment generated the major market share of 90% in 2025.
• By route of administration, the oral treatment segment is expected to grow at the fastest CAGR of 18.83% during the forecast period.

What is the Stomach Cancer Treatment?

Stomach cancer treatment deals with the therapies and other medical procedures that are applied to manage and cure cancer disease that originates from the stomach. Stomach cancer, also known as gastric cancer, develops due to chronic inflammation in the stomach, which can also lead to intestinal metaplasia. The stomach cancer treatment market deals with the manufacturing and distribution of treatments and therapies applied to cure patients. The market is witnessing significant demand due to the increasing demand for various treatments like surgery, chemotherapy , radiation therapy , and many others. The World Cancer Research Fund states that stomach cancer is the 5th most common cancer worldwide.

What is the role of AI in the stomach cancer treatment market?

Technologies like artificial intelligence (AI) and machine learning (ML) are playing an impactful role in the healthcare sector, including the stomach cancer treatment market. The major role of AI in these treatments is to analyze medical imaging and convey medical abnormalities that can enhance treatment outcomes. AI also analyses the data and helps in creating personalized treatment plans. The use of AI in R&D activities is also beneficial in boosting the analyzing process, as the tools can improve the process by analyzing chemical compounds in the research process. The rising investments in these tools are also anticipated to create more precision in AI-assisted surgery outcomes.

Stomach Cancer Treatment Market Growth Factors

• The rise in global cancer incidences due to many reasons, like changing lifestyles and other conditions, has been playing a crucial role in the development of the stomach cancer treatment market.
• The growth in treatments like immunotherapy is playing a crucial role in enhancing treatment outcomes, contributing to market growth.
• The increasing credibility of biosimilars stands out as a major growth factor as they provide cost-effective solutions in cancer treatment.
• The dietary changes of individuals also contribute to the growth of cancer incidences due to unhealthy habits like smoking and alcohol consumption.

Market Scope

Market Dynamics

Driver

Increasing healthcare expenditure in developing countries

The rapid urbanization in developing countries has led to the need for improvisation across various industries, including healthcare. Multiple factors like changing lifestyles in these regions are increasing the disease-prone population. This leads to increasing developments in the healthcare facilities within the regions, including cancer treatments. The rising disposable incomes in countries like China, Mexico, Thailand, and others increase the affordability of these people to afford these treatments. Technological advancements in therapies are being adopted to enhance the patients' experience.

Rise in the aging population

According to the American Cancer Society, the average of people diagnosed with stomach cancer is 68, and around 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. The stomach cancer treatment market grows due to the increasing changes in the human body of elderly people that make them more prone to these diseases. Additionally, these populations also have other health conditions like diabetes and other CADs, which increases the complications in the treatment procedures and leads to the demand for more efficient and result-oriented results.

Restraint

Higher costs of advanced therapies

Technological evolution has marked significant growth in the majority of the developed and developing regions, but there are still some factors that tend to affect market growth. The stomach cancer treatment market has also managed to adopt advanced therapies due to its outcomes, which can be financially unaffordable for underdeveloped regions. This often leads to medical tourism, which also stands as a restraining factor for low-income patients.

Opportunities

Rising awareness among individuals

The rise of new media, i.e., the means of mass communication using the internet, has been playing a vital role in increasing health awareness among individuals, especially adults. The stomach cancer treatment market stands out with numerous opportunities as the patients are opting for early diagnosis and treatment after witnessing symptoms regarding these diseases, which are weight loss, stomach pain, and many more. This demand is leading to significant advancements in the health screening processes, which can help individuals with early detection and treatments that can lead to successful outcomes.

Government policies and regulatory support

The rising incidence of cancer has caught the attention of the health ministries of various governments, which are attracting significant funding for the development. The stomach cancer treatment market has been growing significantly due to the support of various governments. For example, the Indian government provides funds for poor cancer patients under ‘Rashtriya Arogya Nidhi.' Additionally, many governments have availed free screening programs for people to come up and undergo these tests for early detection. The rising drug approval rate for these conditions will also help in providing medications for poor people at lower costs.

Segment Insights

Treatment Type Insights

The targeted therapy segment marked its dominance over the market in 2025. The treatment includes the use of drugs to identify cancer cells and control their growth according to their needs. The stomach cancer treatment market has been witnessing significant demand due to the use of these therapies for a longer period, as they are considered to be safe and efficient. The outcomes of these therapies are effective due to the presence of HER2-targeted drugs. Additionally, these therapies can be applied to various stages of the disease, which increases its availability in the majority of the regions. The widespread demand for these drugs is also leading to more innovation in these therapies for more result-oriented treatments.

The immunotherapy segment is anticipated to grow rapidly in the market from 2026 to 2035. The treatment works to improve the immune system and identify and destroy cancer cells. The growth of these therapies is attributed to the rapid innovation in advanced solutions that can provide long-term benefits to patients in some cases. The expansion of the treatment options also makes these therapies more reliant on these diseases. The stomach cancer treatment market is anticipated to grow more efficiently due to the increasing research practices for enhancement in these services.

Disease Indication Insights

The gastric cancer/gastroesophageal junction cancer segment stood dominant over the market in 2025. This cancer develops where the esophagus meets the stomach. The stomach cancer treatment market is growing due to the increasing number of individuals who smoke. Unhealthy dietary habits also contribute to the increasing number of these cases. The changing lifestyles of individuals have established proper treatment options for these conditions, which generates more opportunities in the healthcare industry. Additionally, the increasing regulatory support for the promotion of health screening contributes to market growth.

The gastrointestinal stromal tumors segment is expected to grow significantly during the forecast period of 2026 to 2035. This is a rare cancer disease that is formed in the tissues of the gastrointestinal (GI) tract. The main cause of the disease is genetic mutation, which makes it rare. The stomach cancer treatment market is growing efficiently due to the rapid advancements in therapies like imatinib, sunitinib, and many more, which focus on treatment outcomes. The professionals are also focusing on research to develop more accurate treatment procedures to cure these diseases. The rising advancements will also contribute to improving the credibility of these treatments.

Drug Class Insights

The PD-1/PD-L1 inhibitors segment is expected to grow at the highest CAGR during the forecast period of 2026 to 2035. These are part of the immunotherapy drugs which are used to treat cancer. The growth in immunotherapy is also leading towards the growth of these drugs, contributing to the growth of the stomach cancer treatment market. The rising drug approval rates are also anticipated to drive more demand in the upcoming years.

Route of Administration Insights

The injectable treatment segment dominated the global market in 2025. The segment refers to the administration of drugs directly into the muscles and bloodstreams, which are most effective due to their quick absorption. This makes it more popular in the advanced cancer stages like chemotherapy, where the drugs are injected through injections. It is a worldwide formula used in these treatments that contributes to the growth of the stomach cancer treatment market.

The oral treatment segment will grow rapidly in the market during the forecast period of 2026 to 2035. The administration of the drugs is done with the help of capsules, pills, and other liquid medications, which are gaining popularity due to the changing patient preferences for more convenient treatment options. This is leading to the growth of many medications that can help in cancer treatment. The stomach cancer treatment market is gaining popularity due to the innovation of these oral treatment options, which are considered to be more cost-effective as compared to the injectables.

Regional Insights

What is the Asia Pacific Stomach Cancer Treatment Market Size?

The Asia Pacific stomach cancer treatment market size was exhibited at USD 3.40 billion in 2025 and is projected to be worth around USD 10.88 billion by 2035, growing at a CAGR of 12.33% from 2026 to 2035.

Asia Pacific dominated the global stomach cancer treatment market in 2025. The dominance of the region is attributed to the higher patient rates in countries like China and Japan. For instance, China reported 246,550 stomach cancer cases in men in 2022 which calculates almost around 10% of the cancer disease.

The increasing health conditions have led to the growth in the healthcare infrastructure which is providing business opportunities in the region. Additionally, governments in the region are also implementing policies which promote health screening for individuals.

Japan Stomach Cancer Treatment Market Trends

Japan has the most advanced practices in oncology, such as targeted therapies, which enhance treatment outcomes. Molecular profiling aids in the accurate selection of therapy. Robotics improves the precision and recovery of surgery. Prevention measures minimize the burden of disease. The emphasis is shifted to the control of high-risk groups using more advanced treatment methods and changing clinical standards in healthcare systems.

Middle East and Africa is anticipated to grow at the highest CAGR in the stomach cancer treatment market during the forecast period of 2025 to 2034. The growth of the region is attributed to the increasing awareness regarding stomach cancer which boosts the healthcare infrastructure in countries like UAE and Saudi Arabia. Additionally, the changing dietary habits of this population may increase the risk of these conditions in the coming years.

UAE Stomach Cancer Treatment Market Trends

UAE grows with fast healthcare development. The availability of innovative therapies enhances treatment. Internationalization of clinical research enhances competencies. Targeted drugs are adopted faster when there are faster approvals. Investments in healthcare contribute to the growth of oncology care. The increase in attention to high-risk groups promotes the need to find more sophisticated and accessible treatments for stomach cancer.

Stomach Cancer Treatment Market Companies

• Mylan N.V. : Offers a gene ric mitomycin injection that is applied as part of the therapy in treating stomach and pancreatic cancer.
• Teva Pharmaceutical Industries Ltd: Invests in novel therapies in collaboration with innovative drugs in all forms of cancer treatment.
• CELLTRION INC. : Provides trastuzumab biosimilar to treat stomach cancer that is advanced in the cases of HER2 and has advanced capabilities to develop antibody drugs.
• Samsung Bioepis: Offers trastuzumab biosimilar in major markets worldwide in metastatic gastric cancer of the HER2 type.

Other Major Key Players

• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• Merck & Co., Inc.
• Bristol-Myers Squibb Company

Latest Announcements by Industry Leaders

• In August 2024, HUTCHMED's CEO, Weiguo Su, announced that fruquintinib combined with paclitaxel shows promise as a future treatment for gastric cancer, and further investigation into its potential will continue.

Segments Covered in the Report

By Treatment Type

• Standard Chemotherapy
• Targeted Therapy
• Immunotherapy

By Disease Indication

• Gastric Cancer/Gastroesophageal Junction Cancer
• Gastrointestinal Stromal Tumors

By Route of Administration

• Oral
• Injectable

By Drug Class

• PD-1/PD-L1 Inhibitors
• HER2 Antagonists
• VEGFR Antagonists
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa